最終更新時刻：2012年5月18日(金) 18時00分
タグ「of」を含む記事一覧
The Overall Value of the Lighting Market Will Shrink as Energy Efficient LEDs Displace Conventional Technology, According to Pike Research
BOULDER, Colo.--(BUSINESS WIRE)--Revenues from LED lamps in the commercial sector will rise by 8.5% through 2021, to $2.7 billion, Pike Research forecasts, although the overall market for commercial lighting will contract.
Sales 47,983mn Yen YY2.7% / Ordinary Income 2,212mn Yen YY-3.0% QTR Results of TAKE AND GIVE. NEEDS (Magical Pocket News)
TOKYO--(BUSINESS WIRE)--TAKE AND GIVE. NEEDS Co., Ltd (TOKYO:4331) News: Company Name TAKE AND GIVE. NEEDS Co.,Ltd Company Code TOKYO:4331 Market Tokyo Stock Exchange Section 1st section Industry Service Fiscal year end March 31 Announce date May 11, ...
Dr. Reddy’s Announces the Launch of Clopidogrel Tablets, USP
HYDERABAD, India--(BUSINESS WIRE)--Dr. Reddy’s Laboratories (NYSE: RDY) announced today that it has launched CLOPIDOGREL TABLETS, USP 75 mg & 300 mg, a bioequivalent generic version of PLAVIX®, in the U.S. market on May 18, 2012. The ANDAs for Clopidogr...
Taiwan Medical Expertise Supports Global Health: A Case of Rebirth
TAIPEI, Taiwan--(BUSINESS WIRE)--Taiwan Medical Expertise Supports Global Health: A Case of Rebirth
Dow Corning and Hemlock Semiconductor Reaction to Preliminary U.S. Department of Commerce Determination Regarding Solar Tariffs
MIDLAND, Mich.--(BUSINESS WIRE)--Dow Corning and Hemlock Semiconductor reaction to Department of Commerce decision on China solar tariffs.
Research and Markets: Future Growth Potential of Mobile Money in China: Market Profile
DUBLIN--(BUSINESS WIRE)--Dublin - Research and Markets (http://www.researchandmarkets.com/research/l2934v/future_growth_pote) has announced the addition of the "Future Growth Potential of Mobile Money in China: Market Profile" report to their offering. ...
Research and Markets: Future Growth Potential of Mobile Money in China: Market Profile
DUBLIN--(BUSINESS WIRE)--Dublin - Research and Markets (http://www.researchandmarkets.com/research/l2934v/future_growth_pote) has announced the addition of the "Future Growth Potential of Mobile Money in China: Market Profile" report to their offering. ...
Positive Phase 2 Clinical Data with Tivantinib in Hepatocellular Carcinoma to Be Highlighted in Oral Presentation at 2012 Annual Meeting of American Society of Clinical Oncology
WOBURN, Mass. & TOKYO--(BUSINESS WIRE)--ArQule and Daiichi Sankyo announced positive Phase 2 clinical data with tivantinib in hepatocellular carcinoma to be presented at ASCO 2012.
Positive Phase 2 Clinical Data with Tivantinib in Hepatocellular Carcinoma to Be Highlighted in Oral Presentation at 2012 Annual Meeting of American Society of Clinical Oncology
WOBURN, Mass. & TOKYO--(BUSINESS WIRE)--ArQule and Daiichi Sankyo announced positive Phase 2 clinical data with tivantinib in hepatocellular carcinoma to be presented at ASCO 2012.
Kotak Mahindra Bank goes live with SmartStream’s TLM Corona for automation of Nostro Reconciliations
LONDON--(BUSINESS WIRE)--Kotak Mahindra Bank goes live with TLM Corona for automation of Nostro Reconciliations to reconcile cash and manage investigation process
Kotak Mahindra Bank goes live with SmartStream’s TLM Corona for automation of Nostro Reconciliations
LONDON--(BUSINESS WIRE)--Kotak Mahindra Bank goes live with TLM Corona for automation of Nostro Reconciliations to reconcile cash and manage investigation process
AVEO and Astellas Announce Positive Findings from TIVO-1 Superiority Study of Tivozanib in First-Line Advanced RCC
CAMBRIDGE, Mass. & TOKYO--(BUSINESS WIRE)--AVEO Oncology (NASDAQ:AVEO) and Astellas Pharma Inc. (TSE:4503) today announced that detailed data from TIVO-1 (Tivozanib Versus Sorafenib in 1st line Advanced RCC), will be presented on June 2 in an oral sessi...
AVEO and Astellas Announce Positive Findings from TIVO-1 Superiority Study of Tivozanib in First-Line Advanced RCC
CAMBRIDGE, Mass. & TOKYO--(BUSINESS WIRE)--AVEO Oncology (NASDAQ:AVEO) and Astellas Pharma Inc. (TSE:4503) today announced that detailed data from TIVO-1 (Tivozanib Versus Sorafenib in 1st line Advanced RCC), will be presented on June 2 in an oral sessi...
Emulex Named Perfect Quality Supplier of the Year by Lenovo
COSTA MESA, Calif. & BEIJING--(BUSINESS WIRE)--Emulex was named Perfect Quality Supplier of the Year by Lenovo at Lenovo's Global Supplier Conference.
Emulex Named Perfect Quality Supplier of the Year by Lenovo
COSTA MESA, Calif. & BEIJING--(BUSINESS WIRE)--Emulex was named Perfect Quality Supplier of the Year by Lenovo at Lenovo's Global Supplier Conference.
ニュース
supported by
Google News API
グローバルニュース
supported by
Business Wire
